The cell and gene therapy market size has grown exponentially in recent years. It will grow from $21.33 billion in 2025 to $26.21 billion in 2026 at a compound annual growth rate (CAGR) of 22.9%. The growth in the historic period can be attributed to limited availability of cell and gene therapies, reliance on conventional treatment modalities, high cost of early-generation therapies, growing incidence of oncology and neurological disorders, lack of specialized treatment centers.
The cell and gene therapy market size is expected to see exponential growth in the next few years. It will grow to $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of advanced car-t and genome editing therapies, expansion of clinical trials and research programs, increasing adoption of personalized medicine, rising government support and funding for rare disease treatments, integration of digital platforms for therapy monitoring and patient management. Major trends in the forecast period include increasing adoption of car-t and stem cell therapies, rising investment in gene therapy for oncology and rare diseases, growth in personalized and targeted cell-based treatments, expansion of hospital and ambulatory surgical centers offering advanced therapies, integration of genome editing and viral vector-based technologies in clinical practice.
A growing number of ongoing clinical trials is expected to propel the growth of the cell and gene therapy market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials play a vital role in the development and advancement of cell and gene therapy. They provide a safe and controlled environment to test new therapies and collect data on their safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, a growing number of ongoing clinical trials is driving the growth of the cell and gene therapy market.
Major companies operating in the cell and gene therapy market are increasing their focus on introducing agnostic systems to gain a competitive edge in the market. Agnostic systems refer to systems that are integrated with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system that aims to improve connectivity across the cell and gene therapy (CGT) treatment journey to enable an enhanced patient and provider experience. The hub is powered by the company's customer relationship management system and is designed to speed up the benefits investigation process, give a real-time view of therapy development and transportation status, and assist in coordinating patient support.
In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company that develops and sells drugs to improve human health and well-being worldwide, acquired Orchard Therapeutics for an undisclosed amount. With this acquisition, Kyowa Kirin Co. Ltd. aims to enhance its capabilities in developing innovative gene therapies for rare diseases, expanding its therapeutic portfolio, and addressing unmet medical needs. Orchard Therapeutics plc is a UK-based biotech company that specializes in developing innovative cell and gene therapies.
Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca.
North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the cell and gene therapy market by raising the cost of imported viral vectors, laboratory reagents, and specialized delivery equipment. Segments like CAR-T cell therapy and viral vector-based gene therapy are most affected, with North America, Europe, and Asia-Pacific regions like China and India facing significant import duties. This has increased operational costs and slowed therapy deployment. On the positive side, tariffs have encouraged local manufacturing, investment in domestic R&D, and innovation in cost-effective therapy delivery systems.
The cell and gene therapy market research report is one of a series of new reports that provides cell and gene therapy market statistics, including cell and gene therapy industry global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.
The main types of products in cell and gene therapies are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material. The different applications include oncology, dermatology, musculoskeletal, and others and involve various sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and others.
The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell and gene therapy market size is expected to see exponential growth in the next few years. It will grow to $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of advanced car-t and genome editing therapies, expansion of clinical trials and research programs, increasing adoption of personalized medicine, rising government support and funding for rare disease treatments, integration of digital platforms for therapy monitoring and patient management. Major trends in the forecast period include increasing adoption of car-t and stem cell therapies, rising investment in gene therapy for oncology and rare diseases, growth in personalized and targeted cell-based treatments, expansion of hospital and ambulatory surgical centers offering advanced therapies, integration of genome editing and viral vector-based technologies in clinical practice.
A growing number of ongoing clinical trials is expected to propel the growth of the cell and gene therapy market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials play a vital role in the development and advancement of cell and gene therapy. They provide a safe and controlled environment to test new therapies and collect data on their safety and efficacy. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, a growing number of ongoing clinical trials is driving the growth of the cell and gene therapy market.
Major companies operating in the cell and gene therapy market are increasing their focus on introducing agnostic systems to gain a competitive edge in the market. Agnostic systems refer to systems that are integrated with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system that aims to improve connectivity across the cell and gene therapy (CGT) treatment journey to enable an enhanced patient and provider experience. The hub is powered by the company's customer relationship management system and is designed to speed up the benefits investigation process, give a real-time view of therapy development and transportation status, and assist in coordinating patient support.
In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company that develops and sells drugs to improve human health and well-being worldwide, acquired Orchard Therapeutics for an undisclosed amount. With this acquisition, Kyowa Kirin Co. Ltd. aims to enhance its capabilities in developing innovative gene therapies for rare diseases, expanding its therapeutic portfolio, and addressing unmet medical needs. Orchard Therapeutics plc is a UK-based biotech company that specializes in developing innovative cell and gene therapies.
Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca.
North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the cell and gene therapy market by raising the cost of imported viral vectors, laboratory reagents, and specialized delivery equipment. Segments like CAR-T cell therapy and viral vector-based gene therapy are most affected, with North America, Europe, and Asia-Pacific regions like China and India facing significant import duties. This has increased operational costs and slowed therapy deployment. On the positive side, tariffs have encouraged local manufacturing, investment in domestic R&D, and innovation in cost-effective therapy delivery systems.
The cell and gene therapy market research report is one of a series of new reports that provides cell and gene therapy market statistics, including cell and gene therapy industry global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.
The main types of products in cell and gene therapies are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material. The different applications include oncology, dermatology, musculoskeletal, and others and involve various sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and others.
The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell and Gene Therapy Market Characteristics
3. Cell and Gene Therapy Market Supply Chain Analysis
4. Global Cell and Gene Therapy Market Trends and Strategies
5. Cell and Gene Therapy Market Analysis of End Use Industries
7. Global Cell and Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell and Gene Therapy Total Addressable Market (TAM) Analysis for the Market
9. Cell and Gene Therapy Market Segmentation
10. Cell and Gene Therapy Market Regional and Country Analysis
11. Asia-Pacific Cell and Gene Therapy Market
12. China Cell and Gene Therapy Market
13. India Cell and Gene Therapy Market
14. Japan Cell and Gene Therapy Market
15. Australia Cell and Gene Therapy Market
16. Indonesia Cell and Gene Therapy Market
17. South Korea Cell and Gene Therapy Market
18. Taiwan Cell and Gene Therapy Market
19. South East Asia Cell and Gene Therapy Market
20. Western Europe Cell and Gene Therapy Market
21. UK Cell and Gene Therapy Market
22. Germany Cell and Gene Therapy Market
23. France Cell and Gene Therapy Market
24. Italy Cell and Gene Therapy Market
25. Spain Cell and Gene Therapy Market
26. Eastern Europe Cell and Gene Therapy Market
27. Russia Cell and Gene Therapy Market
28. North America Cell and Gene Therapy Market
29. USA Cell and Gene Therapy Market
30. Canada Cell and Gene Therapy Market
31. South America Cell and Gene Therapy Market
32. Brazil Cell and Gene Therapy Market
33. Middle East Cell and Gene Therapy Market
34. Africa Cell and Gene Therapy Market
36. Cell and Gene Therapy Market Competitive Landscape and Company Profiles
37. Cell and Gene Therapy Market Other Major and Innovative Companies
40. Cell and Gene Therapy Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cell and Gene Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell and gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell and gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell and gene therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Cell Therapy; Gene Therapy2) By Application: Oncology; Neurological Disorders; Other Applications
3) By End User: Hospitals; Ambulatory Surgical Centers; Cancer Care Centers; Wound Care Centers; Other End-Users
Subsegments:
1) By Cell Therapy: Autologous Cell Therapy; Allogeneic Cell Therapy; Stem Cell Therapy; CAR-T Cell Therapy2) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Vector-Based Gene Therapy; Genome Editing Technologies; Antisense Oligonucleotide Therapy
Companies Mentioned: Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; ArrowHead Pharmaceuticals Inc.; Spark Therapeutics; Bluebird Bio Inc.; RegenexBio; Mesoblast Limited; Stempeutics Research Pvt. Ltd.; EdiGene Inc.; Takara Bio; Oxford Biomedica plc; Merck; GenScript; Cellular Biomedicine Group; inStem; Bristol-Myers Squibb; Amgen; Pfizer; Kite Pharma; Freeline Therapeutics; PsiOxus Therapeutics; Herantis Pharma Plc; AstraZeneca
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell and Gene Therapy market report include:- Biogen Inc.
- Novartis AG
- Gilead Sciences
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- ArrowHead Pharmaceuticals Inc.
- Spark Therapeutics
- Bluebird Bio Inc.
- RegenexBio
- Mesoblast Limited
- Stempeutics Research Pvt. Ltd.
- EdiGene Inc.
- Takara Bio
- Oxford Biomedica plc
- Merck
- GenScript
- Cellular Biomedicine Group
- inStem
- Bristol-Myers Squibb
- Amgen
- Pfizer
- Kite Pharma
- Freeline Therapeutics
- PsiOxus Therapeutics
- Herantis Pharma Plc
- AstraZeneca
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 26.21 Billion |
| Forecasted Market Value ( USD | $ 60.58 Billion |
| Compound Annual Growth Rate | 23.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
